Cargando…

Novel multi-component nanopharmaceuticals derived from poly(ethylene) glycol, retro-inverso-Tat nonapeptide and saquinavir demonstrate combined anti-HIV effects

BACKGROUND: Current anti-AIDS therapeutic agents and treatment regimens can provide a dramatically improved quality of life for HIV-positive people, many of whom have no detectable viral load for prolonged periods of time. Despite this, curing AIDS remains an elusive goal, partially due to the occur...

Descripción completa

Detalles Bibliográficos
Autores principales: Wan, Li, Zhang, Xiaoping, Gunaseelan, Simi, Pooyan, Shahriar, Debrah, Olivia, Leibowitz, Michael J, Rabson, Arnold B, Stein, Stanley, Sinko, Patrick J
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1481600/
https://www.ncbi.nlm.nih.gov/pubmed/16635263
http://dx.doi.org/10.1186/1742-6405-3-12
_version_ 1782128273245863936
author Wan, Li
Zhang, Xiaoping
Gunaseelan, Simi
Pooyan, Shahriar
Debrah, Olivia
Leibowitz, Michael J
Rabson, Arnold B
Stein, Stanley
Sinko, Patrick J
author_facet Wan, Li
Zhang, Xiaoping
Gunaseelan, Simi
Pooyan, Shahriar
Debrah, Olivia
Leibowitz, Michael J
Rabson, Arnold B
Stein, Stanley
Sinko, Patrick J
author_sort Wan, Li
collection PubMed
description BACKGROUND: Current anti-AIDS therapeutic agents and treatment regimens can provide a dramatically improved quality of life for HIV-positive people, many of whom have no detectable viral load for prolonged periods of time. Despite this, curing AIDS remains an elusive goal, partially due to the occurrence of drug resistance. Since the development of resistance is linked to, among other things, fluctuating drug levels, our long-term goal has been to develop nanotechnology-based drug delivery systems that can improve therapy by more precisely controlling drug concentrations in target cells. The theme of the current study is to investigate the value of combining AIDS drugs and modifiers of cellular uptake into macromolecular conjugates having novel pharmacological properties. RESULTS: Bioconjugates were prepared from different combinations of the approved drug, saquinavir, the antiviral agent, R.I.CK-Tat9, the polymeric carrier, poly(ethylene) glycol and the cell uptake enhancer, biotin. Anti-HIV activities were measured in MT-2 cells, an HTLV-1-transformed human lymphoid cell line, infected with HIV-1 strain Vbu 3, while parallel studies were performed in uninfected cells to determine cellular toxicity. For example, R.I.CK-Tat9 was 60 times more potent than L-Tat9 while the addition of biotin resulted in a prodrug that was 2850 times more potent than L-Tat9. Flow cytometry and confocal microscopy studies suggest that variations in intracellular uptake and intracellular localization, as well as synergistic inhibitory effects of SQV and Tat peptides, contributed to the unexpected and substantial differences in antiviral activity. CONCLUSION: Our results demonstrate that highly potent nanoscale multi-drug conjugates with low non-specific toxicity can be produced by combining moieties with anti-HIV agents for different targets onto macromolecules having improved delivery properties.
format Text
id pubmed-1481600
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-14816002006-06-22 Novel multi-component nanopharmaceuticals derived from poly(ethylene) glycol, retro-inverso-Tat nonapeptide and saquinavir demonstrate combined anti-HIV effects Wan, Li Zhang, Xiaoping Gunaseelan, Simi Pooyan, Shahriar Debrah, Olivia Leibowitz, Michael J Rabson, Arnold B Stein, Stanley Sinko, Patrick J AIDS Res Ther Research BACKGROUND: Current anti-AIDS therapeutic agents and treatment regimens can provide a dramatically improved quality of life for HIV-positive people, many of whom have no detectable viral load for prolonged periods of time. Despite this, curing AIDS remains an elusive goal, partially due to the occurrence of drug resistance. Since the development of resistance is linked to, among other things, fluctuating drug levels, our long-term goal has been to develop nanotechnology-based drug delivery systems that can improve therapy by more precisely controlling drug concentrations in target cells. The theme of the current study is to investigate the value of combining AIDS drugs and modifiers of cellular uptake into macromolecular conjugates having novel pharmacological properties. RESULTS: Bioconjugates were prepared from different combinations of the approved drug, saquinavir, the antiviral agent, R.I.CK-Tat9, the polymeric carrier, poly(ethylene) glycol and the cell uptake enhancer, biotin. Anti-HIV activities were measured in MT-2 cells, an HTLV-1-transformed human lymphoid cell line, infected with HIV-1 strain Vbu 3, while parallel studies were performed in uninfected cells to determine cellular toxicity. For example, R.I.CK-Tat9 was 60 times more potent than L-Tat9 while the addition of biotin resulted in a prodrug that was 2850 times more potent than L-Tat9. Flow cytometry and confocal microscopy studies suggest that variations in intracellular uptake and intracellular localization, as well as synergistic inhibitory effects of SQV and Tat peptides, contributed to the unexpected and substantial differences in antiviral activity. CONCLUSION: Our results demonstrate that highly potent nanoscale multi-drug conjugates with low non-specific toxicity can be produced by combining moieties with anti-HIV agents for different targets onto macromolecules having improved delivery properties. BioMed Central 2006-04-24 /pmc/articles/PMC1481600/ /pubmed/16635263 http://dx.doi.org/10.1186/1742-6405-3-12 Text en Copyright © 2006 Wan et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Wan, Li
Zhang, Xiaoping
Gunaseelan, Simi
Pooyan, Shahriar
Debrah, Olivia
Leibowitz, Michael J
Rabson, Arnold B
Stein, Stanley
Sinko, Patrick J
Novel multi-component nanopharmaceuticals derived from poly(ethylene) glycol, retro-inverso-Tat nonapeptide and saquinavir demonstrate combined anti-HIV effects
title Novel multi-component nanopharmaceuticals derived from poly(ethylene) glycol, retro-inverso-Tat nonapeptide and saquinavir demonstrate combined anti-HIV effects
title_full Novel multi-component nanopharmaceuticals derived from poly(ethylene) glycol, retro-inverso-Tat nonapeptide and saquinavir demonstrate combined anti-HIV effects
title_fullStr Novel multi-component nanopharmaceuticals derived from poly(ethylene) glycol, retro-inverso-Tat nonapeptide and saquinavir demonstrate combined anti-HIV effects
title_full_unstemmed Novel multi-component nanopharmaceuticals derived from poly(ethylene) glycol, retro-inverso-Tat nonapeptide and saquinavir demonstrate combined anti-HIV effects
title_short Novel multi-component nanopharmaceuticals derived from poly(ethylene) glycol, retro-inverso-Tat nonapeptide and saquinavir demonstrate combined anti-HIV effects
title_sort novel multi-component nanopharmaceuticals derived from poly(ethylene) glycol, retro-inverso-tat nonapeptide and saquinavir demonstrate combined anti-hiv effects
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1481600/
https://www.ncbi.nlm.nih.gov/pubmed/16635263
http://dx.doi.org/10.1186/1742-6405-3-12
work_keys_str_mv AT wanli novelmulticomponentnanopharmaceuticalsderivedfrompolyethyleneglycolretroinversotatnonapeptideandsaquinavirdemonstratecombinedantihiveffects
AT zhangxiaoping novelmulticomponentnanopharmaceuticalsderivedfrompolyethyleneglycolretroinversotatnonapeptideandsaquinavirdemonstratecombinedantihiveffects
AT gunaseelansimi novelmulticomponentnanopharmaceuticalsderivedfrompolyethyleneglycolretroinversotatnonapeptideandsaquinavirdemonstratecombinedantihiveffects
AT pooyanshahriar novelmulticomponentnanopharmaceuticalsderivedfrompolyethyleneglycolretroinversotatnonapeptideandsaquinavirdemonstratecombinedantihiveffects
AT debraholivia novelmulticomponentnanopharmaceuticalsderivedfrompolyethyleneglycolretroinversotatnonapeptideandsaquinavirdemonstratecombinedantihiveffects
AT leibowitzmichaelj novelmulticomponentnanopharmaceuticalsderivedfrompolyethyleneglycolretroinversotatnonapeptideandsaquinavirdemonstratecombinedantihiveffects
AT rabsonarnoldb novelmulticomponentnanopharmaceuticalsderivedfrompolyethyleneglycolretroinversotatnonapeptideandsaquinavirdemonstratecombinedantihiveffects
AT steinstanley novelmulticomponentnanopharmaceuticalsderivedfrompolyethyleneglycolretroinversotatnonapeptideandsaquinavirdemonstratecombinedantihiveffects
AT sinkopatrickj novelmulticomponentnanopharmaceuticalsderivedfrompolyethyleneglycolretroinversotatnonapeptideandsaquinavirdemonstratecombinedantihiveffects